SEC Form 4 · accession 0002114156-26-000003
NovaBridge Biosciences · NBP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Liwei Lorraine Lin
Officer — General Counsel
Period of report
Jul 8, 2026
Accepted (ET)
Jul 10, 2026 · 5:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001778016
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 Employee Share Option (right to buy)F1,F2,F3 | $1.93 | Jul 8, 2026 | A | 254,780 | A | — | Jul 8, 2036 | Ordinary Shares | 254,780 | 254,780 | D |
Explanation of responses
- F1Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS").
- F2The option vests and becomes exercisable over five years, with 40% vesting on the second anniversary of February 1, 2026 and the balance vesting in three equal annual installments thereafter.
- F3The Ordinary Shares may be represented by ADSs. Each 10 ADSs represent 23 Ordinary Shares of the Issuer.